Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001415889-25-010958
Filing Date
2025-04-17
Accepted
2025-04-17 18:26:40
Documents
2
Period of Report
2025-04-15

Document Format Files

Seq Description Document Type Size
1 form3-04172025_100437.html 3  
1 form3-04172025_100437.xml 3 1678
2 ex24-04172025_100437.htm EX-24 6216
  Complete submission text file 0001415889-25-010958.txt   9526
Mailing Address 3 SUGAR CREEK CTR. BLVD. STE 525 SUGAR LAND TX 77478
Business Address 3 SUGAR CREEK CTR. BLVD. STE 525 SUGAR LAND TX 77478 (713) 489-8654
Tvardi Therapeutics, Inc. (Issuer) CIK: 0001346830 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 5956 SHERRY LN 1810 DALLAS TX 75225
Business Address
HALL WALLACE L JR (Reporting) CIK: 0001762801 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-36279 | Film No.: 25848754